Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC41 Phase 2 Study in NASH
NCT05462353Phase 2Active, not recruiting
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Sep 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ASC-41 in Nonalcoholic steatohepatitis (NASH), sponsored by Gannex Pharma Co., Ltd.. Started Sep 2022; status: active, not recruiting.
02
Drugs
ASC-41
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05462353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462353.